Clinical trial NCT02462369 - References

Microalbuminuria — Saxagliptin's Effects on Microalbuminuria Improvement in Type 2 Diabetic Patients

Citation(s)

•   Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M
  Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care. 2013 Nov;36(11):3460-8. doi: 10.2337/dc13-0
•   Hattori S
  Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2011;58(1):69-73. Epub 2010 Dec 28.
•   Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS
  Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther. 2012 Feb;340(2):248-55. doi: 10.1124/jpet.111.186866. Epub 2011 Oct
•   Mosenzon O, Bhatt DL, Likwat L, et al
  Effect of saxagliptin on renal outcomes. 2014 ADA poster. 544-P.
•   Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG; DEMAND investigators
  Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006 Jun;69(11):2057-63.
•   Phung OJ, Scholle JM, Talwar M, Coleman CI
  Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010 Apr 14;303(14):1410-8. doi: 10.1001/jama.2010.405.

The Effects of Saxagliptin 5mg, Once Daily for 52 Weeks on 24 Hour Urine Albumin Creatinine Rate(ACR) , in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin or/and Acarbose

Details for clinical trial NCT02462369